Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trial.

Tobacco induced diseases·2026
Same author

Validation of photoplethysmography-derived short-term heart rate variability using a wearable device.

Scientific reports·2026
Same author

Linezolid in addition to standard antibiotic treatment for <i>Staphylococcus aureus</i> bacteraemia: study protocol for a randomised, placebo-controlled trial.

BMJ open·2026
Same author

Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort Study.

Trials·2026
Same author

Barriers and Facilitators of Platform Trials.

JAMA network open·2026
Same author

Effect of different recruiter attire on trial participation in Lesotho: a randomized study within a trial.

Trials·2026
Same journal

<sup>18</sup>F-FDG PET/MRI for non-invasive risk stratification of Intraductal Papillary Neoplasms of the Bile Duct (IPNB).

European journal of nuclear medicine and molecular imaging·2026
Same journal

Real-world evaluation of [<sup>177</sup>Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Subcortical dopamine D<sub>2</sub> receptor availability and glucose metabolism in autism: a dual-tracer PET/MR study.

European journal of nuclear medicine and molecular imaging·2026
Same journal

PET-based assessment of coronary microvascular dysfunction and its relation to plaque burden and vascular remodeling: integration with microvascular resistance reserve.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours.

European journal of nuclear medicine and molecular imaging·2026
Same journal

PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracer <sup>18</sup>F-S2P in preclinical models.

European journal of nuclear medicine and molecular imaging·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Towards tailored radiopeptide therapy.

Piotr Radojewski1, Rebecca Dumont, Nicolas Marincek

  • 1Institute of Nuclear Medicine, University Hospital Bern, 3010, Bern, Switzerland.

European Journal of Nuclear Medicine and Molecular Imaging
|March 21, 2015
PubMed
Summary
This summary is machine-generated.

Combining radioisotopes in somatostatin receptor-targeted radiopeptide therapy improves survival for neuroendocrine tumor patients. This dual radioisotope approach, using Yttrium-90 and Lutetium-177, also shows reduced hematotoxicity compared to single agents.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.4K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmacology

Background:

  • Somatostatin receptor-targeted radiopeptide therapy is a standard treatment for neuroendocrine tumors.
  • Current practice often involves single radioisotope administration.

Purpose of the Study:

  • To evaluate the benefits and harms of combining radioisotopes in radiopeptide therapy for neuroendocrine tumor patients.
  • To compare outcomes of combined (90)Y-DOTATOC and (177)Lu-DOTATOC therapy versus single-agent therapies.

Main Methods:

  • Multivariable-adjusted survival analyses and competing risk analyses were employed.
  • Outcomes were evaluated in patients receiving (90)Y-DOTATOC, (177)Lu-DOTATOC, or their combination.

Main Results:

  • Combined (90)Y-DOTATOC and (177)Lu-DOTATOC therapy was associated with significantly longer survival compared to either single agent.
  • (177)Lu-DOTATOC alone demonstrated improved survival over (90)Y-DOTATOC in specific patient subgroups, including those with solitary lesions or extrahepatic metastases.
  • (90)Y-DOTATOC treatment resulted in higher hematotoxicity rates than the combined approach or (177)Lu-DOTATOC alone, with similar renal toxicity across all treatments.

Conclusions:

  • The combination of (90)Y and (177)Lu offers a promising strategy for tailoring radiopeptide therapy.
  • This approach may lead to improved survival outcomes for patients with neuroendocrine tumors.